Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $60.00 at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) had its target price boosted by stock analysts at Canaccord Genuity Group from $36.00 to $60.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 79.10% from the company’s previous close.

STOK has been the topic of several other research reports. Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. Guggenheim began coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Thursday. Finally, HC Wainwright boosted their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Stoke Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $41.83.

Stoke Therapeutics Stock Up 0.9%

STOK stock traded up $0.31 during midday trading on Friday, reaching $33.50. 2,012,441 shares of the company’s stock traded hands, compared to its average volume of 777,802. The company has a 50-day simple moving average of $32.60 and a two-hundred day simple moving average of $29.93. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $40.22. The company has a market cap of $1.98 billion, a price-to-earnings ratio of 50.00 and a beta of 1.07.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Adrian R. Krainer sold 33,243 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the transaction, the director directly owned 283,302 shares in the company, valued at approximately $11,258,421.48. This represents a 10.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 6,686 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24. Following the completion of the transaction, the insider directly owned 40,798 shares in the company, valued at $1,278,609.32. This trade represents a 14.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 69,699 shares of company stock valued at $2,526,714 over the last ninety days. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently bought and sold shares of STOK. AQR Capital Management LLC grew its holdings in Stoke Therapeutics by 1.2% during the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after acquiring an additional 354 shares during the period. Strs Ohio lifted its stake in shares of Stoke Therapeutics by 9.4% in the 4th quarter. Strs Ohio now owns 7,000 shares of the company’s stock valued at $222,000 after purchasing an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after purchasing an additional 658 shares during the period. Generali Investments Management Co LLC boosted its position in shares of Stoke Therapeutics by 41.0% in the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock worth $78,000 after purchasing an additional 718 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in shares of Stoke Therapeutics in the 4th quarter worth $26,000.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Several research firms reaffirmed or raised bullish views and price targets on STOK, signaling analyst-driven demand and upside potential; Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
• Positive Sentiment: BTIG, Wedbush and Needham published bullish notes or raised targets (BTIG reaffirmed Buy with a $39 target; Wedbush boosted its target to $38), which can attract momentum buyers and support the rally. BTIG Research reaffirmation (Benzinga)
• Positive Sentiment: Clinical coverage emphasized STK‑001’s potential beyond seizure control—reporting that the program aims to reverse developmental loss in Dravet syndrome, a narrative that supports longer‑term valuation. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Market analysis pieces examined a recent sharp pullback and drivers behind it—useful context for traders but not a new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
• Negative Sentiment: Significant insider selling was disclosed March 17–19 across multiple executives (CFO, General Counsel and others), with double‑digit percentage trims in positions—this cluster of sales can weigh on sentiment and invites investor caution; representative SEC filing. SEC Form 4 (Jonathan Allan)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.